LCM
SRPT icon

Lucas Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Lucas Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-6,625
Closed -$876K – 85
2018
Q2 		$876K Buy
6,625
+1,625
+33% +$153K 0.83% 34
2018
Q1 		$377K Sell
5,000
-500
-9% -$33.3K 0.36% 56
2017
Q4 		$306K Hold
5,500
– – 0.27% 74
2017
Q3 		$249K Buy
+5,500
New +$220K 0.22% 86

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Lucas Capital Management's SRPT Position: Q3 2018 in Review

Lucas Capital Management sold out of Sarepta Therapeutics (SRPT) in Q3 2018, closing a stake of 6,625 shares — an estimated $876K sold.

Lucas Capital Management first reported a position in SRPT in Q3 2017 and held it in 4 quarters. The position peaked at $876K in Q2 2018. 344 funds tracked by Wall St. Rank hold SRPT as of Q3 2018.

  • Lucas Capital Management reported no remaining Sarepta Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Lucas Capital Management sold 6,625 Sarepta Therapeutics shares in Q3 2018, an estimated $876K.
  • Lucas Capital Management first reported a position in Sarepta Therapeutics in Q3 2017 and held it in 4 quarters.
  • Lucas Capital Management's Sarepta Therapeutics position peaked at $876K in Q2 2018.
  • 344 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2018.

Based on Lucas Capital Management's 13F filing for Q3 2018, filed 26 Oct 2018.